SEC Filing Analysis: MediWound Ltd. (MDWD)

Executive Summary

• Trading Significance: High
• Key Takeaway: Institutional investor Rosalind Advisors, Inc. has reaffirmed its significant 7.0% ownership stake in MediWound Ltd., a holding valued at approximately $16.4 million.
• Market Impact: Neutral. This filing confirms an existing, substantial position rather than a new transaction, reinforcing the status quo of a large institutional holder's conviction in the small-cap biotech company.

Company Information

Field	Value
Company	MediWound Ltd.
Ticker Symbol	MDWD
CIK	0001593984
Industry	Medicinal Chemicals & Botanical Products

Insider Information

Field	Value
Name	Rosalind Advisors, Inc. (and related parties)
CIK	0001622627
Title/Position	Investment Advisor
Relationship	Significant Shareholder (>5%)

Transaction Details

This Schedule 13G/A is a statement of beneficial ownership and not a report of a specific transaction.

Field	Value
Form Type	SCHEDULE 13G/A
Event Date	2025-12-31
Transaction Code	N/A
Security Type	Common Shares and Warrants
Shares Involved	N/A
Price Per Share	N/A
Total Value	N/A
Shares Owned After	912,319
Ownership Type	Indirect

Financial Impact Assessment

Holding Materiality

Metric	Value
Total Shares Held	912,319
Estimated Holding Value	~$16.4 million (based on $230M market cap and 12.82M shares outstanding)
% of Market Cap	~7.1%
% of Shares Outstanding	7.1%
Post-Transaction Ownership	912,319 shares (7.0% of class, per filing)
Materiality Assessment	Highly Significant

Impact Evaluation

• Market Cap Context: For a company with a market capitalization of $230 million, a single institutional holding of over $16 million is substantial. It represents a concentrated bet by the investment advisor.
• Ownership Concentration: A 7.0% stake makes Rosalind Advisors a major shareholder with significant influence. This level of ownership is a strong signal of conviction.
• Dilution Impact: The holding includes 163,265 shares issuable upon warrant exercise. If exercised, this would represent approximately 1.27% of the current shares outstanding, a minor dilution event.
• Transaction Significance: The significance lies not in a single transaction but in the size and continuation of the holding. A 7% stake is well above the 0.5% threshold for a highly significant position.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: As an amendment to a previous 13G, this filing confirms an existing position. It does not signal a new buy or sell, so it is unlikely to cause a significant, immediate price movement. It does, however, provide a positive anchor for valuation.

Volume & Sentiment

• Expected Volume Impact: Low. Schedule 13G filings, especially amendments, are informational and typically do not drive trading volume unless they reveal a new activist intent, which is not the case here (passive filing).
• Sentiment Indicator: Neutral to Bullish. The continued holding by a major institution is a bullish sign of long-term confidence. However, the lack of a new purchase keeps the immediate sentiment neutral.

Investment Insights

Positive Market Indicators

• Strong Institutional Conviction: A 7.0% stake indicates deep conviction from a professional investment firm.
• Significant Ownership: The size of the stake provides a degree of stability and validation for the company's prospects.

Risk Factors

• Concentration Risk: While a positive signal, a large concentrated holding also poses a risk. A future decision by the fund to liquidate its position could create significant downward pressure on the stock price.

Key Takeaways

1. Major Stake Reaffirmed: Rosalind Advisors continues to be a major shareholder in MediWound with a 7.0% beneficial ownership stake.
2. Significant Position Size: The holding is valued at over $16 million, representing a material portion of the company's $230 million market cap.
3. Passive Investment: The filing certifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the company.

Additional Context

Transaction Notes

• The filing is an amendment (No. 9) to a previous Schedule 13G, reporting the filer's ownership as of year-end 2025. The ownership is held indirectly through Rosalind Master Fund L.P., for which Rosalind Advisors, Inc. acts as the investment advisor.